Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies
Arrowhead gains on AAT deficiency data
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002 study. At 24 weeks, the RNAi therapy decreased levels of mutant AAT protein in the liver by up to 95%, decreased biomarkers of liver injury by up to 66% and improved liver stiffness measured by a FibroScan in the open label study. Shares of the company rose $13.63 (40%) to $47.43.
Metacrine slips in NASDAQ debut
Metacrine Inc. (NASDAQ:MTCR) fell $1.24 (10%) to $11.76 in its first day of trading. The liver and GI company raised $85 million through the sale of 6.5 million shares at $13, the midpoint of its proposed range...